Isofraxidin demonstrates protective effects against high-fat diet-induced hepatic lipid metabolism disorders and inflammation in a mouse model.
Answers are grounded in this paper and cite their sources.
May support isofraxidin for metabolic liver inflammation; leaves open human translation from this animal model.
macrophages) and inflammatory cytokine release (TNFα and IL-6). Moreover, the anti-inflammatory activity in IF-treated hepatic tissue correlated with down-regulation of TLR4 expression and NF-κB transcription. In sum, these results suggest that IF might play a protective role against lipid metabolism disorder induced by a high-fat diet via inhibition of lipid production and inflammation in the liver.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: